MX2019000796A - Moleculas multimericas de union a ox40 y usos de las mismas. - Google Patents
Moleculas multimericas de union a ox40 y usos de las mismas.Info
- Publication number
- MX2019000796A MX2019000796A MX2019000796A MX2019000796A MX2019000796A MX 2019000796 A MX2019000796 A MX 2019000796A MX 2019000796 A MX2019000796 A MX 2019000796A MX 2019000796 A MX2019000796 A MX 2019000796A MX 2019000796 A MX2019000796 A MX 2019000796A
- Authority
- MX
- Mexico
- Prior art keywords
- binding molecules
- multimeric
- hexameric
- pentameric
- methods
- Prior art date
Links
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364763P | 2016-07-20 | 2016-07-20 | |
| PCT/US2017/043165 WO2018017888A1 (en) | 2016-07-20 | 2017-07-20 | Multimeric ox40 binding molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000796A true MX2019000796A (es) | 2019-06-03 |
Family
ID=60996094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000796A MX2019000796A (es) | 2016-07-20 | 2017-07-20 | Moleculas multimericas de union a ox40 y usos de las mismas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190330374A1 (OSRAM) |
| EP (1) | EP3487533A4 (OSRAM) |
| JP (1) | JP2019530640A (OSRAM) |
| CN (1) | CN109562165A (OSRAM) |
| AU (1) | AU2017298483A1 (OSRAM) |
| CA (1) | CA3030647A1 (OSRAM) |
| IL (1) | IL263799A (OSRAM) |
| MX (1) | MX2019000796A (OSRAM) |
| WO (1) | WO2018017888A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
| BR112016018313A8 (pt) | 2014-02-10 | 2018-06-12 | Igm Biosciences Inc | Moléculas de ligação multiespecíficas iga |
| CN112759650B (zh) | 2014-04-03 | 2024-10-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| KR102435324B1 (ko) | 2015-01-20 | 2022-08-23 | 아이쥐엠 바이오사이언스 인코포레이티드 | 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도 |
| SI3265575T1 (sl) | 2015-03-04 | 2021-08-31 | Igm Biosciences, Inc. | Vezne molekule CD20 in njihove uporabe |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2016249404B2 (en) | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| ES2996834T3 (en) | 2015-09-30 | 2025-02-13 | Igm Biosciences Inc | Binding molecules with modified j-chain |
| CA3021669A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| WO2018187702A2 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences A/S | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| BR112020017296A2 (pt) | 2018-03-01 | 2020-12-29 | Igm Biosciences, Inc. | Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm |
| WO2020063668A1 (zh) * | 2018-09-25 | 2020-04-02 | 信达生物制药(苏州)有限公司 | 包含抗ox40抗体的制剂、其制备方法及其用途 |
| JP2022505663A (ja) * | 2018-10-23 | 2022-01-14 | アイジーエム バイオサイエンシズ インコーポレイテッド | ＩｇＭ－Ｆｃベース及びＩｇＡ－Ｆｃベースの多価結合分子 |
| CN110172090B (zh) * | 2019-06-03 | 2020-04-03 | 中山标佳生物科技有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
| CN114269785A (zh) | 2019-08-15 | 2022-04-01 | Igm生物科学股份有限公司 | 免疫刺激性多聚体结合分子 |
| CN115485299A (zh) | 2020-04-22 | 2022-12-16 | Igm生物科学股份有限公司 | Pd-1激动剂多聚结合分子 |
| CN112957475B (zh) * | 2021-02-04 | 2022-07-22 | 李文峰 | 一种预防和或治疗肿瘤的组合物及应用 |
| US20220332837A1 (en) * | 2021-04-08 | 2022-10-20 | Colorado State University Research Foundation | Methods and compositions for ox40 activation in treatment of canine cancer |
| US20250236653A1 (en) * | 2024-01-22 | 2025-07-24 | Onko-Innate Pty Ltd | Targeted low potency il-12 fc fusion proteins and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US9382319B2 (en) * | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| ES2740358T3 (es) * | 2012-02-06 | 2020-02-05 | Providence Health & Services Oregon | Método de supervisión del tratamiento del cáncer con agonistas de OX40 |
| CA2943834A1 (en) * | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| JP7328761B2 (ja) * | 2016-01-11 | 2023-08-17 | インヒブルクス インコーポレイテッド | 多価多重特異性ｏｘ４０結合融合タンパク質 |
-
2017
- 2017-07-20 EP EP17831908.3A patent/EP3487533A4/en not_active Withdrawn
- 2017-07-20 WO PCT/US2017/043165 patent/WO2018017888A1/en not_active Ceased
- 2017-07-20 US US16/317,814 patent/US20190330374A1/en not_active Abandoned
- 2017-07-20 JP JP2019502573A patent/JP2019530640A/ja not_active Withdrawn
- 2017-07-20 CN CN201780044931.3A patent/CN109562165A/zh active Pending
- 2017-07-20 MX MX2019000796A patent/MX2019000796A/es unknown
- 2017-07-20 CA CA3030647A patent/CA3030647A1/en not_active Abandoned
- 2017-07-20 AU AU2017298483A patent/AU2017298483A1/en not_active Abandoned
-
2018
- 2018-12-18 IL IL263799A patent/IL263799A/en unknown
-
2022
- 2022-02-17 US US17/673,864 patent/US20220169751A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018017888A1 (en) | 2018-01-25 |
| US20190330374A1 (en) | 2019-10-31 |
| US20220169751A1 (en) | 2022-06-02 |
| JP2019530640A (ja) | 2019-10-24 |
| CN109562165A (zh) | 2019-04-02 |
| CA3030647A1 (en) | 2018-01-25 |
| AU2017298483A1 (en) | 2019-02-07 |
| EP3487533A1 (en) | 2019-05-29 |
| IL263799A (en) | 2019-02-28 |
| EP3487533A4 (en) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000796A (es) | Moleculas multimericas de union a ox40 y usos de las mismas. | |
| MX2019000799A (es) | Moleculas de union a gitr multimericas y usos de las mismas. | |
| NZ762365A (en) | Cd20 binding molecules and uses thereof | |
| IL266100A (en) | Multimeric il-15 based molecules | |
| PH12020550781A1 (en) | Anti-jagged1 antibodies and methods of use | |
| PH12017501039A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| CO2017004386A2 (es) | Fluidos de estimulación de lgn de grado y | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| PH12016502142A1 (en) | Anti-ptk7 antibody-drug conjugates | |
| MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| PH12017501748B1 (en) | Antibodies to icos | |
| MX2017006094A (es) | Anticuerpos anti-interleucina-33 y sus usos. | |
| MY193661A (en) | Anti-tim3 antibodies and methods of use | |
| MX2015012334A (es) | Metodos y composiciones para el control de malezas. | |
| MX387665B (es) | Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos. | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
| EP3103025A4 (en) | Content based organization of file systems | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| MX2016009858A (es) | Fusiones anti proteína convertasa subtilisina/kexina tipo 9 (anti-pcsk9)n péptido 1 similar a glucagón (glp-1) y métodos de uso. | |
| EP3091229A4 (en) | Method of driving constant volume pump, device for driving constant volume pump, vaporizer and anesthesia device | |
| MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
| MX2019005833A (es) | Administracion transdermica de agentes grandes. | |
| PT3227797T (pt) | Sistema e método para correlação de ficheiros funcional rápida e escalável |